secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001683168-24-007710
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic extends Scripps collaboration with $400k funding for DNase platform
---------------------------------------------------------------------------

- Extended Research Funding & Option Agreement with Scripps Research by 12 months; total funding up to ~$400,000.
- Initial $65k payment on Nov 1, 2024, followed by ~$65k monthly payments over 5 months.
- Focus: systemic DNase I combined with CAR T-cell therapies for hematological cancers and melanoma.
- Xenetic holds option to acquire exclusive license to new IP from the DNase research program.
- Advancing DNase oncology platform toward Phase 1 for pancreatic carcinoma and solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824007710/0001683168-24-007710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824007710/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-007710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer